1IntroductionImatinib, a Bcr-Abl kinase inhibitor is the standard therapy for all phases of CML [1]. Imatinib also inhibits other kinases, including ABL, c-kit, PDGFR-α and -β, ARG and c-fms. While the activity against these targets is being exploited therapeutically, it may also underlie some of the adverse effects reported. The most common adverse effects include superficial oedema, nausea, muscle cramps, musculoskeletal pain, rash, fatigue, diarrhoea and myelosuppression [2]. Ocular toxicities...